{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:05:52Z","timestamp":1790867152844,"version":"4.1.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Tuberculosis (TB), caused by\n                      <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                      (MTB), remains the leading cause of death from a single infectious agent worldwide. Drug-resistant TB (DR-TB) poses a major challenge. Bedaquiline (BDQ) is central to multidrug resistant tuberculosis\/extensively drug-resistant TB (MDR\/XDR-TB) treatment, yet emerging resistance prompted this study to assess its prevalence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This prospective observational study was conducted in the TB culture and drug susceptibility testing (DST) laboratory of a tertiary care hospital over 9 months. Sputum samples from presumptive DR-TB cases were included, whereas extrapulmonary and nontuberculous mycobacteria samples were excluded from the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 1190 samples were subjected to the first-line probe assay (LPA) for drug resistance detection in MTB. MDR-TB was most common, followed by mono-isoniazid and monorifampicin resistance. Of 512 DR-TB samples tested by second-line probe assay (SL-LPA), 25 yielded invalid results. Fluoroquinolone (FQ) resistance was highest (47.7%), whereas second-line injectable drug (SLID) resistance was rare (1.4%); combined FQ + SLID resistance occurred in 10.7% samples, whereas 35.4% samples were sensitive. Among 380 isolates subjected to liquid culture DST, resistance was detected to moxifloxacin (7.4%), linezolid (2.1%), and BDQ (0.78%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>BDQ resistance is low but emerging; routine DST, rational drug use, and robust surveillance are vital to preserve BDQ efficacy and ensure effective DR-TB management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_224_25","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:00:15Z","timestamp":1774641615000},"page":"20-25","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence of Bedaquiline Resistance among Drug Resistant \u2013 Tuberculosis Cases at a Tertiary Healthcare Setting in Metropolitan City of Maharashtra, India"],"prefix":"10.4103","volume":"15","author":[{"given":"Shraddha","family":"Dalvi","sequence":"first","affiliation":[{"name":"Department of Microbiology, GGMC and Sir J. J. Group of Hospitals, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poulami","family":"Biswas","sequence":"additional","affiliation":[{"name":"Department of Microbiology, GGMC and Sir J. J. Group of Hospitals, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shatabdi","family":"Bhagat","sequence":"additional","affiliation":[{"name":"Department of Microbiology, GGMC and Sir J. J. Group of Hospitals, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6068-4246","authenticated-orcid":false,"given":"Nilma","family":"Hirani","sequence":"additional","affiliation":[{"name":"Department of Microbiology, GGMC and Sir J. J. Group of Hospitals, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"R1-20260416","doi-asserted-by":"crossref","first-page":"107325","DOI":"10.1016\/j.ijid.2024.107325","article-title":"Insights from the 2024 WHO Global Tuberculosis Report \u2013 More comprehensive action, innovation, and investments required for achieving WHO End TB goals","volume":"150","author":"Goletti","year":"2025","journal-title":"Int J Infect Dis"},{"key":"R2-20260416","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/jpdtsm.jpdtsm_117_23","article-title":"Linezolid associated neurologic toxicity in patients with drug resistant tuberculosis in a bedaquiline based regimen: A scoping review","volume":"2","author":"Putra","year":"2023","journal-title":"J Prev Diagn Treat Strateg Med"},{"key":"R3-20260416","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4103\/ijmr.IJMR_1048_18","article-title":"Trends and treatment outcomes of multidrug-resistant tuberculosis in Delhi, India (2009-2014): A retrospective record-based study","volume":"151","author":"Sharma","year":"2020","journal-title":"Indian J Med Res"},{"key":"R4-20260416","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4103\/jpdtsm.jpdtsm_64_25","article-title":"Antimycobacterial efficacy of hydroethanolic leaf extracts from selected medicinal plants traditionally used against Mycobacterium tuberculosis","volume":"4","author":"Nguta","year":"2025","journal-title":"J Prev Diagn Treat Strateg Med"},{"issue":"Suppl 1","key":"R6-20260416","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ijmyco.2016.10.038","article-title":"Tuberculosis in children","volume":"5","author":"Velayati","year":"2016","journal-title":"Int J Mycobacteriol"},{"key":"R7-20260416","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/INF.0000000000001270","article-title":"Pediatric extrapulmonary tuberculosis: Clinical spectrum, risk factors and diagnostic challenges in a low prevalence region","volume":"35","author":"Santiago-Garc\u00eda","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R8-20260416","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/jpdtsm.jpdtsm_144_23","article-title":"Tuberculosis prevention, diagnosis, and treatment financial profile during 2006\u20132021: Part B","volume":"3","author":"Madadi Goli","year":"2024","journal-title":"J Prev Diagn Treat Strateg Med"},{"key":"R10-20260416","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4103\/ijmy.ijmy_143_23","article-title":"A critical review of risk factors influencing the prevalence of extensive drug-resistant tuberculosis in India","volume":"12","author":"Khan","year":"2023","journal-title":"Int J Mycobacteriol"},{"key":"R11-20260416","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"R12-20260416","doi-asserted-by":"crossref","first-page":"17552","DOI":"10.1038\/s41598-020-74432-y","article-title":"Prevalence and factors associated with multidrug-resistant tuberculosis in South India","volume":"10","author":"Shivekar","year":"2020","journal-title":"Sci Rep"},{"key":"R13-20260416","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s11033-024-10014-9","article-title":"Prevalence of rifampicin and isoniazid mono-resistance among cases of pulmonary tuberculosis from Western Uttar Pradesh, North India","volume":"51","author":"Kumar","year":"2024","journal-title":"Mol Biol Rep"},{"key":"R14-20260416","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13073-022-01076-0","article-title":"High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region","volume":"14","author":"Dreyer","year":"2022","journal-title":"Genome Med"},{"key":"R15-20260416","doi-asserted-by":"crossref","first-page":"19719","DOI":"10.1038\/s41598-024-70535-y","article-title":"Risk assessment and transmission of fluoroquinolone resistance in drug-resistant pulmonary tuberculosis: A retrospective genomic epidemiology study","volume":"14","author":"Nehru","year":"2024","journal-title":"Sci Rep"},{"key":"R16-20260416","doi-asserted-by":"crossref","first-page":"e0291920","DOI":"10.1128\/JCM.02919-20","article-title":"Bedaquiline drug resistance emergence assessment in multidrug-resistant tuberculosis (MDR-TB): A 5-year prospective in vitro surveillance study of bedaquiline and other second-line drug susceptibility testing in MDR-TB isolates","volume":"60","author":"Kaniga","year":"2022","journal-title":"J Clin Microbiol"},{"key":"R17-20260416","doi-asserted-by":"crossref","first-page":"100481","DOI":"10.1016\/j.jctube.2024.100481","article-title":"Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study","volume":"37","author":"Khan","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"R18-20260416","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s12879-025-11067-2","article-title":"Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: A systematic review and meta-analysis","volume":"25","author":"Hu","year":"2025","journal-title":"BMC Infect Dis"},{"key":"R19-20260416","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4103\/lungindia.lungindia_495_24","article-title":"Newer regimen for drug resistant-tuberculosis: A ray of hope or threatening shadows","volume":"42","author":"Mehta","year":"2025","journal-title":"Lung India"},{"issue":"Suppl 1","key":"R20-20260416","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.4103\/2212-5531.307061","article-title":"Emergence of resistance to bedaquiline","volume":"10","author":"De Vos","year":"2021","journal-title":"Int J Mycobacteriol"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_224_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:58:01Z","timestamp":1786647481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_224_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_224_25","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-11-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}